StockNews.com Initiates Coverage on IRIDEX (NASDAQ:IRIX)

Stock analysts at StockNews.com initiated coverage on shares of IRIDEX (NASDAQ:IRIX) in a report released on Sunday. The firm set a “hold” rating on the medical equipment provider’s stock.

IRIDEX Stock Up 4.1 %

Shares of NASDAQ IRIX opened at $1.76 on Friday. The company’s 50 day moving average price is $1.67 and its 200-day moving average price is $2.01. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.86 and a current ratio of 1.54. IRIDEX has a 52-week low of $1.27 and a 52-week high of $3.65. The company has a market capitalization of $29.28 million, a P/E ratio of -2.63 and a beta of 0.80.

IRIDEX (NASDAQ:IRIX) last released its earnings results on Tuesday, November 12th. The medical equipment provider reported ($0.12) earnings per share (EPS) for the quarter. The firm had revenue of $11.58 million during the quarter. IRIDEX had a negative net margin of 22.79% and a negative return on equity of 192.95%. During the same quarter last year, the firm posted ($0.11) EPS.

About IRIDEX

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.